Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02387203 · ClinicalTrials.gov registry record · Phase 2

Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin

A Phase 2 study of Appendiceal Neoplasms and Pseudomyxoma Peritonei, sponsored by Mercy Medical Center.

Active
Registry status
Phase 2
Development phase
80
Enrollment target
1
Study location

NCT02387203 is a Phase 2 study of Appendiceal Neoplasms and Pseudomyxoma Peritonei that is active but no longer recruiting, run by Mercy Medical Center. The registered enrollment target is 80 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02387203, a Phase 2 study of Appendiceal Neoplasms and Pseudomyxoma Peritonei, is active but no longer recruiting, sponsored by Mercy Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the impact of antibiotic therapy on the disease progression and overall survival of patients with Pseudomyxoma Peritonei (PMP).

Interventions

  • DRUG PrevPac (Prevacid, Amoxicillin, Clarithromycin)

Study Locations (1)

Maryland

  • Mercy Medical Center - Baltimore

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2015-01
Est. Completion 2024-12
Phase Phase 2

Sponsor

Mercy Medical Center

13 total trials

What the Registry Record Tells You About NCT02387203

The ClinicalTrials.gov registry entry for NCT02387203 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mercy Medical Center, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Appendiceal Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which PrevPac (Prevacid, Amoxicillin, Clarithromycin) is the first listed.

NCT02387203 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT02387203 about?

NCT02387203 is a clinical study titled "Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin". The purpose of this study is to determine the impact of antibiotic therapy on the disease progression and overall survival of patients with Pseudomyxoma Peritonei (PMP).

What is the current status of trial NCT02387203?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2015-01. Estimated completion is 2024-12.

What conditions does trial NCT02387203 study?

This clinical trial studies the following conditions: Appendiceal Neoplasms, Pseudomyxoma Peritonei.

What interventions are being tested in trial NCT02387203?

The interventions under investigation include: PrevPac (Prevacid, Amoxicillin, Clarithromycin) (DRUG).

Who is sponsoring clinical trial NCT02387203?

This trial is sponsored by Mercy Medical Center, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02387203 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.